Next Generation

Immuno-Oncology Therapeutics

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of drug candidates that target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response.

>> More about immuno-oncology



Clinical Efficacy in Two Indications

Our lead immuno-oncology candidate APG101 is in clinical development for the treatment of a variety of solid tumors and malignant hematological diseases. It has demonstrated statistically significant efficacy in a controlled phase II proof-of-concept trial in recurrent glioblastoma. Patients with a certain biomarker experienced the greatest benefit from treatment with APG101. Apogenix is developing a companion diagnostic test based on this biomarker, so APG101 can be used as a personalized therapy.



The Apogenix team has created the HERA technology platform for the development of novel hexavalent receptor agonists that target different TNFSF-dependent signaling pathways, which play a crucial role in the regulation of the immune response. These fusion proteins offer clear therapeutic advantages over other biologics such as antibodies and have the potential for broad application in oncology.



July 19, 2016
Apogenix Granted European Patent for the Use of APG101 in the Treatment of Myelodysplastic Syndromes

July 14, 2016
 "Apogenix hex on TNF", BioCentury Innovation article on the relevance of HERA as a novel immuno-oncology drug development tool platform